VistaGen Therapeutics logo

VistaGen Therapeutics

2 Followers

About

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multi...

No jobs yet!

Team announcement

VistaGen Therapeutics names Dr. Louis Monti VP, Translational Medicine

VistaGen Therapeutics names Dr. Louis Monti VP, Translational Medicine

Biopharmaceutical company VistaGen Therapeutics has hired Dr. Louis Monti as Vice President, Translational Medicine. Dr. Monti is an expert in the research and development of neuroactive steroids, known as pherines. He comes to VistaGen from Pherin Pharmaceuticals, where he served as Vice President of Research and Executive Vice President, before being made President and CEO in 2018. He has also held academic positions at the University of Utah, and the University of the Republic, Uruguay. "We have had the pleasure of working closely with Dr. Monti in a consultative capacity since 2018 to complement our efforts to develop PH94B and PH10 to improve the lives of millions of people worldwide who suffer from anxiety and depression disorders every day," said VistaGen Chief Executive Officer Shawn K. Singh. "As we approach several potentially significant milestones for these differentiated neuropsychiatric drug candidates in 2021 and beyond, Dr. Monti's unique knowledge, expertise, and insight about their potential, as well as potential opportunities for further expansion of our CNS pipeline, will be valuable. We are excited that he has now joined us as a full-time member of our R&D team." "Driving research of neuroactive pherines to develop innovative medicines with the potential to lift the burdens of anxiety and depression has been a passion throughout my career,” said Dr. Monti. “I am truly pleased to join a team that shares that sense of commitment and purpose. I am excited that my new role at VistaGen will allow me both to continue to assist with the late-stage clinical development of PH94B and PH10 and apply my R&D experience working with neuroactive steroids to explore potential pipeline expansion opportunities."

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.